Unknown OBSERVATIONAL NCT05243173

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Sponsor: RenJi Hospital

Conditions FH-Deficient RCC Metabolomics Renal Cell Carcinoma Systemic Treatments

Interventions Sequencing

Updated 5 times since 2022 Last updated: Aug 15, 2022 Started: May 25, 2022 Primary completion: Jun 30, 2024 Completion: Jun 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on FH-Deficient RCC and Metabolomics, this trial is ongoing. The trial is conducted by RenJi Hospital and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Jul 2024 — Sep 2024 [monthly]

Recruiting
Sep 2022 — Jul 2024 [monthly]

Recruiting
Jul 2022 — Sep 2022 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Jul 2022 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China